Duodenal Ulcer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Duodenal Ulcer – Drugs In Development, 2024 report and make more profitable business decisions.
Duodenal ulcers, a subset of peptic ulcer disease, result from a disruption in the mucosal surface of the duodenum, the initial segment of the small intestine. The primary culprit behind this condition is infection with Helicobacter pylori (H. pylori) bacteria. H. pylori induces inflammation in the duodenal lining, leading to ulcer formation. Certain medications, especially anti-inflammatory drugs like ibuprofen and aspirin, can also contribute to duodenal ulcers. Treatment commonly involves “triple therapy”, utilizing two antibiotics and an acid-reducing medicine. The antibiotics target bacteria, while the acid-reducing medication aids in healing the ulcer and preventing recurrence.
The Duodenal Ulcer drugs in development market research report provide comprehensive information on the therapeutics under development for Duodenal Ulcer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duodenal Ulcer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Duodenal Ulcer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Duodenal Ulcer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Duodenal Ulcer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Duodenal Ulcer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Boryung Pharmaceutical Co LtdCalyGene Biotechnology Inc
Changchun Haiyue Pharmaceutical Co Ltd
Dong Wha Pharma Co Ltd
Dongkwang Pharma Co Ltd
GL Pharm Tech Corp
Hanmi Pharmaceuticals Co Ltd
Hunan Mingrui Pharmaceutical Co Ltd
Hunan Sailong Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Sinorda Biomedicine Co Ltd
JW Pharmaceutical Corp
Korea Pharma Co Ltd
Luoxin Pharmaceuticals Group Stock Co Ltd
R-Pharm
Sebela Pharmaceuticals Inc
Sotex Pharm Firm
Xiamen Encheng Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Duodenal Ulcer reports